IFX-1-P2.6: A randomized, double-blind, placebo-controlled, multicenter, parallel-group Phase II study to investigate the safety and efficacy of two different dose regimens of IFX-1 as add-on to standard of care in subjects with granulomatosis with polya
|Effective start/end date||6/1/18 → 12/31/21|
- INFLARX GMBH
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.